Forte Biosciences Files 8-K for Q1 2026 Results
Ticker: FBRX · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001419041
Sentiment: neutral
Topics: financial-results, 8-k, operations
Related Tickers: FBRX
TL;DR
Forte Bio dropped its Q1 2026 earnings report, check the 8-K for deets.
AI Summary
Forte Biosciences, Inc. filed an 8-K on April 1, 2026, reporting its financial results and condition for the period ending March 31, 2026. The filing includes financial statements and exhibits, with specific details on operations and financial condition.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Forte Biosciences, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain new material events or risks.
Key Players & Entities
- Forte Biosciences, Inc. (company) — Filer of the 8-K report
- 0001419041 (company) — CIK number for Forte Biosciences, Inc.
- 2026-04-01 (date) — Filing date of the 8-K
- 2026-03-31 (date) — Period of report for financial results
FAQ
What specific financial metrics are detailed in the Item 2.02 Results of Operations and Financial Condition?
The filing indicates Item 2.02 covers Results of Operations and Financial Condition, but the specific metrics are not detailed in the provided summary text, requiring a review of the attached exhibits.
What is the purpose of the EX-99.1 document?
EX-99.1 is an exhibit to the 8-K filing, likely containing the detailed financial statements and operational information referenced in Item 2.02.
When was Forte Biosciences, Inc. incorporated?
The filing states the State of Incorp. is DE, but the specific incorporation date is not provided in the summary text.
What is the SIC code for Forte Biosciences, Inc.?
The SIC code for Forte Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What are the mailing and business addresses for Forte Biosciences, Inc.?
Both the mailing and business addresses for Forte Biosciences, Inc. are listed as 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2026-04-01 08:00:07
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d63145d8k.htm (8-K) — 25KB
- d63145dex991.htm (EX-99.1) — 49KB
- g63145g0401045902486.jpg (GRAPHIC) — 8KB
- 0001193125-26-135767.txt ( ) — 202KB
- fbrx-20260331.xsd (EX-101.SCH) — 3KB
- fbrx-20260331_lab.xml (EX-101.LAB) — 18KB
- fbrx-20260331_pre.xml (EX-101.PRE) — 11KB
- d63145d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. On March 31, 2026, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits Exhibit Description 99.1 Press Release dated March 31, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: April 1, 2026 By: /s/ Antony Riley Antony Riley Chief Financial Officer